These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
371 related articles for article (PubMed ID: 27809841)
1. Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasis. Conley-LaComb MK; Semaan L; Singareddy R; Li Y; Heath EI; Kim S; Cher ML; Chinni SR Mol Cancer; 2016 Nov; 15(1):68. PubMed ID: 27809841 [TBL] [Abstract][Full Text] [Related]
2. CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone. Chinni SR; Yamamoto H; Dong Z; Sabbota A; Bonfil RD; Cher ML Mol Cancer Res; 2008 Mar; 6(3):446-57. PubMed ID: 18337451 [TBL] [Abstract][Full Text] [Related]
3. CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models. Gravina GL; Mancini A; Muzi P; Ventura L; Biordi L; Ricevuto E; Pompili S; Mattei C; Di Cesare E; Jannini EA; Festuccia C Prostate; 2015 Sep; 75(12):1227-46. PubMed ID: 26073897 [TBL] [Abstract][Full Text] [Related]
4. CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12. Chinni SR; Sivalogan S; Dong Z; Filho JC; Deng X; Bonfil RD; Cher ML Prostate; 2006 Jan; 66(1):32-48. PubMed ID: 16114056 [TBL] [Abstract][Full Text] [Related]
5. PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling. Conley-LaComb MK; Saliganan A; Kandagatla P; Chen YQ; Cher ML; Chinni SR Mol Cancer; 2013 Jul; 12(1):85. PubMed ID: 23902739 [TBL] [Abstract][Full Text] [Related]
6. CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy. Domanska UM; Timmer-Bosscha H; Nagengast WB; Oude Munnink TH; Kruizinga RC; Ananias HJ; Kliphuis NM; Huls G; De Vries EG; de Jong IJ; Walenkamp AM Neoplasia; 2012 Aug; 14(8):709-18. PubMed ID: 22952424 [TBL] [Abstract][Full Text] [Related]
7. G protein‑mediated EGFR transactivation is a common mechanism through which the CXCL12 receptors, CXCR4 and CXCR7, control human cancer cell migration. Zieger-Naumann K; Kuhl F; Engele J Oncol Rep; 2024 Feb; 51(2):. PubMed ID: 38099418 [TBL] [Abstract][Full Text] [Related]
8. The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signaling. Berning P; Schaefer C; Clemens D; Korsching E; Dirksen U; Potratz J Cell Commun Signal; 2018 May; 16(1):21. PubMed ID: 29776413 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of CXCR4/CXCL12 signaling axis by ursolic acid leads to suppression of metastasis in transgenic adenocarcinoma of mouse prostate model. Shanmugam MK; Manu KA; Ong TH; Ramachandran L; Surana R; Bist P; Lim LH; Kumar AP; Hui KM; Sethi G Int J Cancer; 2011 Oct; 129(7):1552-63. PubMed ID: 21480220 [TBL] [Abstract][Full Text] [Related]
10. The CXCL12/CXCR4 axis promotes ligand-independent activation of the androgen receptor. Kasina S; Macoska JA Mol Cell Endocrinol; 2012 Apr; 351(2):249-63. PubMed ID: 22245379 [TBL] [Abstract][Full Text] [Related]
11. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. Sun YX; Schneider A; Jung Y; Wang J; Dai J; Wang J; Cook K; Osman NI; Koh-Paige AJ; Shim H; Pienta KJ; Keller ET; McCauley LK; Taichman RS J Bone Miner Res; 2005 Feb; 20(2):318-29. PubMed ID: 15647826 [TBL] [Abstract][Full Text] [Related]
12. Adaptor proteins mediate CXCR4 and PI4KA crosstalk in prostate cancer cells and the significance of PI4KA in bone tumor growth. Govindarajan B; Sbrissa D; Pressprich M; Kim S; Rishi AK; Vaishampayan U; Cher ML; Chinni SR Sci Rep; 2023 Nov; 13(1):20634. PubMed ID: 37996444 [TBL] [Abstract][Full Text] [Related]
13. Suppressing the formation of lipid raft-associated Rac1/PI3K/Akt signaling complexes by curcumin inhibits SDF-1α-induced invasion of human esophageal carcinoma cells. Lin ML; Lu YC; Chen HY; Lee CC; Chung JG; Chen SS Mol Carcinog; 2014 May; 53(5):360-79. PubMed ID: 23192861 [TBL] [Abstract][Full Text] [Related]
14. A novel cross-talk between CXCR4 and PI4KIIIα in prostate cancer cells. Sbrissa D; Semaan L; Govindarajan B; Li Y; Caruthers NJ; Stemmer PM; Cher ML; Sethi S; Vaishampayan U; Shisheva A; Chinni SR Oncogene; 2019 Jan; 38(3):332-344. PubMed ID: 30111818 [TBL] [Abstract][Full Text] [Related]
15. Growth factor receptor-Src-mediated suppression of GRK6 dysregulates CXCR4 signaling and promotes medulloblastoma migration. Yuan L; Zhang H; Liu J; Rubin JB; Cho YJ; Shu HK; Schniederjan M; MacDonald TJ Mol Cancer; 2013 Mar; 12():18. PubMed ID: 23497290 [TBL] [Abstract][Full Text] [Related]
16. Proinflammatory CXCL12-CXCR4/CXCR7 Signaling Axis Drives Myc-Induced Prostate Cancer in Obese Mice. Saha A; Ahn S; Blando J; Su F; Kolonin MG; DiGiovanni J Cancer Res; 2017 Sep; 77(18):5158-5168. PubMed ID: 28687617 [TBL] [Abstract][Full Text] [Related]
17. AMD3100 inhibits epithelial-mesenchymal transition, cell invasion, and metastasis in the liver and the lung through blocking the SDF-1α/CXCR4 signaling pathway in prostate cancer. Zhu WB; Zhao ZF; Zhou X J Cell Physiol; 2019 Jul; 234(7):11746-11759. PubMed ID: 30537000 [TBL] [Abstract][Full Text] [Related]
18. Androgen receptor and chemokine receptors 4 and 7 form a signaling axis to regulate CXCL12-dependent cellular motility. Hsiao JJ; Ng BH; Smits MM; Wang J; Jasavala RJ; Martinez HD; Lee J; Alston JJ; Misonou H; Trimmer JS; Wright ME BMC Cancer; 2015 Mar; 15():204. PubMed ID: 25884570 [TBL] [Abstract][Full Text] [Related]